Search Within

Timothy Chan

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (98)
  2. Meeting Abstract (37)
  3. Review (5)
  4. Research Letter (2)
  5. Editorial (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (143)
  2. GSK Faculty (143)
  3. Sloan Kettering Institute Postdocs (143)
  4. Department of Medicine (70)
  5. Surgery (68)
  6. Solid Tumor Oncology Division (61)

More Groups

People
  1. Vladimir Makarov (39)
  2. Luc Morris (36)
  3. Fengshen Kuo (33)
  4. Abraham Hakimi (27)
  5. Nadeem Riaz (27)
  6. Sevin Turcan (22)

More People

Years
  1. 2023 (1)
  2. 2022 (13)
  3. 2021 (14)
  4. 2020 (20)
  5. 2019 (16)
  6. 2018 (16)

More Years

Publications
  1. Clinical Cancer Research (10)
  2. Nature Genetics (10)
  3. Cancer Research (9)
  4. International Journal of Radiation Oncology, Biology, Physics (8)
  5. Journal of Clinical Oncology (8)
  6. Nature Communications (8)

More Publications

Publishers
  1. Nature Publishing Group (30)
  2. American Association for Cancer Research (26)
  3. Oxford University Press (16)
  4. Biomed Central Ltd (10)
  5. Cell Press (9)
  6. Elsevier Inc. (9)

More Publishers

Results (143)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase
    Journal Article

    Valero, C.; Lee, M.; Hoen, D.; Zehir, A.; Berger, M. F.; Seshan, V. E.; Chan, T. A.; Morris, L. G. T.
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Qa-1(b) modulates resistance to anti–PD-1 immune checkpoint blockade in tumors with defects in antigen processing
    Journal Article

    Zhang, X.; Sabio, E.; Krishna, C.; Ma, X.; Wang, J.; Jiang, H.; Havel, J. J.; Chan, T. A.
    Molecular Cancer Research (2021)

    Fulltext@MSK | Save
  • Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
    Journal Article

    Krishna, C.; DiNatale, R. G.; Kuo, F.; Srivastava, R. M.; Vuong, L.; Chowell, D.; Gupta, S.; Vanderbilt, C.; Purohit, T. A.; Liu, M.; more...
    Cancer Cell (2021)

    Fulltext@MSK | Save
  • Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT)
    Meeting Abstract

    Rappold, P. M.; Silagy, A. W.; Kuo, F.; Marker, M.; Reising, A.; Millholland, J.; Russo, P.; Coleman, J.; Voss, M. H.; Chan, T. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Putative drivers of aggressiveness in TCEB1-mutant renal cell carcinoma: An emerging entity with variable clinical course
    Journal Article

    DiNatale, R. G.; Gorelick, A. N.; Makarov, V.; Blum, K. A.; Silagy, A. W.; Freeman, B.; Chowell, D.; Marcon, J.; Mano, R.; Sanchez, A.; more...
    European Urology Focus (2021)

    Fulltext@MSK | Save
  • Pathogenic ATM mutations in cancer and a genetic basis for radiotherapeutic efficacy
    Journal Article

    Pitter, K. L.; Casey, D. L.; Lu, Y. C.; Hannum, M.; Zhang, Z.; Song, X.; Pecorari, I.; McMillan, B.; Ma, J.; Samstein, R. M.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
    Journal Article

    Valero, C.; Lee, M.; Hoen, D.; Weiss, K.; Kelly, D. W.; Adusumilli, P. S.; Paik, P. K.; Plitas, G.; Ladanyi, M.; Postow, M. A.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • The association between tumor mutational burden and prognosis is dependent on treatment context
    Research Letter

    Valero, C.; Lee, M.; Hoen, D.; Wang, J.; Nadeem, Z.; Patel, N.; Postow, M. A.; Shoushtari, A. N.; Plitas, G.; Balachandran, V. P.; more...
    Nature Genetics (2021)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Pourpe, S.; Ghosh, A.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J. J.; Pourpe, S.; Ghosh, A.; Bozkus, C. C.; Mangarin, L. M. B.; Redmond, D.; Verma, S.; Schad, S.; more...
    Journal of Immunology (2020)

    Fulltext@MSK | Save